Berlin Metropolitan Area
I am an experienced translational scientist/PhD with a profound interest in oncology, genuinely interested and strongly driven by the urgency for oncology patients care and treatment. I am also a strategic and business-savvy PhD with a strong analytical approach to solve problems. At BioNTech I am heavily involved in shaping the product strategy, portfolio prioritisation and new product planning in both early and late stage development. I am deeply engaged with Pumitamig (BNT327) and in creating the foundational brand strategy for our product(s) as we work towards translating science into survival. Operating in a quite complex pre-commercial environment—further shaped by BioNTech deep scientific roots, our Alliance with Bristol Mayer Squibb—and within our rich and fascinating portfolio is allowing me to develop and showcase sound and effective communication to maintain cross-functional ‘osmosis’ and teamwork. I am also a "fluent" guitar player and a former athlete with official competitions and awards in Muay Thai/Kickboxing/Savate combat disciplines (full contact). ------------------------------ Opinions, conclusions or other info posted are personal, unless indicated otherwise.
Oncology BU
• Proven expertise in assays development and CRISPR/Cas9 gene engineering in a novel manuscript on cancer stem cells metabolism as a lead author, with implications for personalized cancer therapies. • Successful derivation of induced Pluripotent Stem Cells (iPSCs) with wild type, mutant and knock-out p53 gene in less than 10 months slashing project costs by 20%. • Extensive hands-on experience with mammalian cell culture (tumor-derived cell lines, primary mesenchymal stem cells, embryonic stem cells, iPSCs, cancer cell lines), cell-based and in vivo/ex-vivo assays. • Gained leadership experience and led Ph.D., M.Sc. students and lab staff, in 4 different projects advising on the design of experiments and the interpretation of results. • Assisted in raising $800,000 of funding.
• Raised by self-initiative the interest in cancer metabolism in this laboratory, implemented adequate techniques to study metabolic alterations and initiated several follow-up metabolism-related projects and new collaborations. • Independently developed protocols for in-vitro and ex-vivo assays aimed at defining the metabolic profile of cancer cells, tumor-derived cultures and stem cells. • Developed protocols for sampling and processing of tissues (ex vivo tumors) and cells for extraction of metabolites and proteins to be assessed by GC/MS or LC/MS (metabolomics). • Analyzed and interpreted with creative thinking highly complex data sets, interconnecting results from bioinformatics, molecular and cell biology assays and became an expert in interpreting complex metabolic and cell signaling networks.